SCHEMBL3662725

SCHEMBL3662725

COc1ccc(Cl)cc1C(=O)N1CCC(Nc2nc3ccc(Cl)cc3o2)C1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SSTR5 P35346 5/20 0.48
ALDH1A1 P00352 2/20 0.45
KDM4E B2RXH2 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
GFER P55789 1/20 0.44
THRB P10828 2/20 0.42
HCRTR2 O43614 2/20 0.42
S1PR3 Q99500 1/20 0.41
CDK1 P06493 1/20 0.41
CDK4 P11802 1/20 0.41
CCND1 P24385 1/20 0.41
CDK2 P24941 1/20 0.41
HRH1 P35367 1/20 0.41
HTR2B P41595 1/20 0.41
HCRTR1 O43613 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8223857 0.96 SSTR5 (0.46) SSTR5ALDH1A1KDM4ECYP1A2CYP2C9
SCHEMBL4245283 0.95 GFER (0.51) SSTR5ALDH1A1KDM4ECYP1A2CYP2C9
SCHEMBL4238380 0.93 SSTR5 (0.53) SSTR5ALDH1A1KDM4ECYP1A2CYP2C9
SCHEMBL8224297 0.93 HCRTR2 (0.48) SSTR5HCRTR2CDK2HCRTR1
SCHEMBL8227080 0.91 SSTR5 (0.46) SSTR5HCRTR2CDK2HCRTR1
SCHEMBL8225957 0.89 GAA (0.49) SSTR5GFERTHRBHCRTR2CDK2
SCHEMBL3660605 0.88 HCRTR1 (0.50) SSTR5THRBHCRTR2HCRTR1
SCHEMBL3656379 0.88 HCRTR1 (0.50) SSTR5THRBHCRTR2HCRTR1
SCHEMBL8224268 0.88 SSTR5 (0.46) SSTR5GFERHCRTR2CDK2HCRTR1
SCHEMBL8218039 0.86 CCNK (0.50) SSTR5ALDH1A1HCRTR2CDK2HCRTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7897627-B2 Heteroaryl derivatives as orexin receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2011-03-01 US disclosed
US-7897627-B2 Heteroaryl derivatives as orexin receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2011-03-01 US disclosed
US-7897627-B2 Heteroaryl derivatives as orexin receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2011-03-01 US disclosed
EP-2234999-A1 HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2010-10-06 EP disclosed
WO-2009080533-A1 HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-07-02 WO disclosed
US-20090163485-A1 HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-06-25 US disclosed
US-20090163485-A1 HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-06-25 US disclosed
US-20090163485-A1 HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163485-A1 HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS HCRTR1, HCRTR2, MTNR1A SSTR5 248/4885ALDH1A1 1037/4885KDM4E 3183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.